EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Microglial SIRT2 deficiency aggravates cognitive decline and amyloid pathology in Alzheimer’s disease

Noemi Sola-Sevilla, Maider Garmendia-Berges, Mikel Aleixo, MCarmen Mera-Delgado, Maite Solas, Rosa M Tordera, Lucía García-Carracedo, Sara Expósito, Elena Anaya-Cubero, Joaquín Fernández-Irigoyen, Elisabeth Guruceaga, Enrique Santamaria und 2 weitere

Brain, Behavior, and Immunity · 2025-10 · 129 · 223-243

DOI: 10.1016/j.bbi.2025.06.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, Behavior, and Immunity, 2025-10. Verfasst von Noemi Sola-Sevilla und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Division of Pharmacology, University of Navarra, 31008 Pamplona, Spain; IdISNA, Navarra Institute for Health R…. Hauptthemen laut MEDLINE: Sirtuin 2, Alzheimer Disease, Microglia, Cognitive Dysfunction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sirtuin 2 (SIRT2), a NAD+-dependent deacetylase, has been implicated in aging and neurodegenerative diseases such as Alzheimer's disease (AD). While global SIRT2 inhibition has shown promise in reducing amyloid-beta pathology and cognitive deficits in different mouse models of AD, peripheral SIRT2 inhibition has been associated with adverse effects, such as increased inflammation. This suggests that targeted inhibition of specific cellular populations within the brain may represent a more precise and effective approach for the treatment of AD. To explore this hypothesis, we generated a conditional microglial SIRT2 knockout mouse model in the context of AD. Our results reveal that microglial SIRT2 reduction does not confer protective effects in the APP/PS1 model; rather, it aggravates cognitive decline, accelerates amyloid plaque deposition, and increases levels of pro-inflammatory cytokines at early stages of AD pathology. Transcriptomic analysis further indicates that SIRT2-deficient microglia exhibit altered expression of genes associated with aging and synaptic dysfunction. This phenotype was accompanied by increased phagocytosis of PSD95 and impaired long-term potentiation. These findings suggest that while SIRT2 inhibition in some contexts may be beneficial, targeted inhibition within microglia could accelerate AD progression, underscoring the need for cell-specific approaches when considering SIRT2 as a therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sirtuin 2Alzheimer DiseaseMicrogliaCognitive DysfunctionAnimalsMiceMice, KnockoutDisease Models, AnimalPlaque, AmyloidBrainMaleAmyloid beta-Peptides

Stichwörter der Autor:innen

AgingAlzheimer’s diseaseMicrogliaNeurodegenerative diseasesNeuroinflammationSirtuin 2

Substanzen

Sirtuin 2Sirt2 protein, mouseAmyloid beta-Peptides

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Division of Pharmacology, University of Navarra, 31008 Pamplona, Spain; IdISNA, Navarra Institute for Health Research, 31008 Pamplona, Spain; Department of Neurology, Research Cent…
  • Department of Pharmaceutical Sciences, Division of Pharmacology, University of Navarra, 31008 Pamplona, Spain; IdISNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.
  • Laboratory of Neurophysiology and Synaptic Plasticity, Instituto Cajal, Consejo Superior de Investigaciones Científicas, Madrid, Spain.
  • Clinical Neuroproteomics Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, 31008 Pamplona, Spain.
  • IdISNA, Navarra Institute for Health Research, 31008 Pamplona, Spain; Bioinformatics Platform, CIMA, University of Navarra, Pamplona, Spain.
  • Department of Pharmaceutical Sciences, Division of Pharmacology, University of Navarra, 31008 Pamplona, Spain; IdISNA, Navarra Institute for Health Research, 31008 Pamplona, Spain. Electronic address: epuerta@unav.es.

Zitieren

APA

Sola-Sevilla, N., Garmendia-Berges, M., Aleixo, M., Mera-Delgado, M., Solas, M., Tordera, R. M., García-Carracedo, L., Expósito, S., Anaya-Cubero, E., Fernández-Irigoyen, J., Guruceaga, E., Santamaria, E., Martin, E. D., & Puerta, E. (2025). Microglial SIRT2 deficiency aggravates cognitive decline and amyloid pathology in Alzheimer’s disease. Brain, Behavior, and Immunity, 129, 223-243. https://doi.org/10.1016/j.bbi.2025.06.016

Vancouver

Sola-Sevilla N, Garmendia-Berges M, Aleixo M, Mera-Delgado M, Solas M, Tordera RM, et al. Microglial SIRT2 deficiency aggravates cognitive decline and amyloid pathology in Alzheimer’s disease. Brain, Behavior, and Immunity. 2025;129:223-243. doi:10.1016/j.bbi.2025.06.016

BibTeX
@article{SolaSevilla2025,
  author = {Sola-Sevilla, Noemi and Garmendia-Berges, Maider and Aleixo, Mikel and Mera-Delgado, MCarmen and Solas, Maite and Tordera, Rosa M and García-Carracedo, Lucía and Expósito, Sara and Anaya-Cubero, Elena and Fernández-Irigoyen, Joaquín and Guruceaga, Elisabeth and Santamaria, Enrique and Martin, Eduardo D and Puerta, Elena},
  title = {Microglial SIRT2 deficiency aggravates cognitive decline and amyloid pathology in Alzheimer’s disease},
  journal = {Brain, Behavior, and Immunity},
  year = {2025},
  volume = {129},
  pages = {223--243},
  doi = {10.1016/j.bbi.2025.06.016}
}
Kostenlos starten →